HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
41 - 50 of 189
Contrast-Enhanced Ultrasound Evaluation of Bowel Perfusion in Necrotizing Enterocolitis
The goal of this study is to develop ultrasound techniques that assess blood supply to the intestines using an investigational contrast agent. Our hope is to contribute to early diagnosis and improved outcomes.
Contrast-Enhanced Ultrasound Evaluation of Hypoxic Ischemic Injury
The goal of this HIE (Hypoxic Ischemic Encephalopathy) Study is to develop ultrasound techniques for detecting impaired blood supply to the brain using an investigational contrast agent.
Copanlisib in Solid Tumors or Lymphoma
The purpose of this study is to find out what is the right dose of copanlisib in children and adolescents, and if your disease responds to this new drug.
CP-SMC Pilot Study
The purpose of this study is to assess deficits in movement and coordination in children with cerebral palsy (CP) and without.
The Craniofacial Pathologies biobank is a research study collecting and storing reamining surgical specimens from the cranium and face from diagnosed patients at CHOP with a congenital craniofacial anomaly.
CrCEST MRI in Mitochondrial Disease
Study focusing on non-invasive MRI procedures to measure biological activity within leg muscles of individuals, including both healthy volunteers and those with mitochondrial disease.
CTX and Idiopathic Bilateral Cataracts in Pediatric Patients
CTX is typically a highly progressive disease, with case reports of symptoms that first appear at any time from birth through adulthood and then worsen over time.
Cure Glomerulonephropathy Network (CureGN) is a multi-year study of 2,400 children and adults with four rare glomerular (kidney) diseases at over 50 centers in the US, Canada, and Italy.
Daratumumab for T-cell ALL
CHOP, in collaboration with Janssen Research & Development, is conducting a study for children and young adults up to 30 years old, with relapsed or refractory precursor T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. This clinical trial is adding the study drug, daratumumab, to a standard relapse chemotherapy regimen.
Dasiglucagon for the Treatment of Children with Congenital Hyperinsulinism (for children under 1 year of age)
This study is a randomized, double-blind, placebo-controlled study that will evaluate the safety and efficacy of dasiglucagon in children between the ages of 7 days and 12 months who have congenital hyperinsulinism.